Biohaven Research Ltd
BHVN
ISIN VGG1110E1079 / Valor 121902526
Biohaven Research Ltd
UMushroom community rating:
About company
Biohaven Research Ltd is a biopharmaceutical company that has demonstrated a strong track record in developing and commercializing innovative therapies, particularly in the field of neurology. The company gained significant attention for its development of Nurtec® ODT (rimegepant), a groundbreaking treatment for migraine, which acts as both a preventive and acute therapy for migraine attacks. This novel CGRP receptor antagonist received approval from the FDA and the European Medicines Agency (EMA), marking a significant milestone in migraine treatment. Prior to its acquisition by Pfizer in May 2022, Biohaven's CGRP platform, including Nurtec ODT, achieved notable success, with Nurtec ODT becoming the leading prescribed medication in its class within two years of its launch in 2020. This achievement underscores Biohaven's capability in not only developing but also effectively commercializing treatments that address critical needs in the healthcare sector, particularly in areas with significant patient demand.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
1025 M
Market cap (USD)
3,382,637
Daily traded volume (Shares)
36.36 / 35.33
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Yam Yi Pan
Misha Batvinov
Jacky Cao
EQUITIES OF THE SAME SECTOR
